Chronic Fatigue Syndrome Clinical Trial
Official title:
Probing Metabolism, Circulating Inflammatory Molecules, Extracellular Vesicles and Immune Dysregulation in Individual Immune Cells in ME/CFS
Verified date | July 2023 |
Source | Ithaca College |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study aims to collect and identify key outcome measures or disease parameters in ME/CFS that are altered during elevated symptoms relative to baseline by gathering information before and after symptom provocation using a two-day cardiopulmonary exercise test.
Status | Completed |
Enrollment | 173 |
Est. completion date | March 31, 2023 |
Est. primary completion date | March 15, 2022 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility | Adults with ME/CFS: Inclusion Criteria: - Diagnosed with ME/CFS - Adults 18 to 70 years of age Exclusion Criteria: - Recent history of panic attacks within the past 6 months - Diagnosis of schizophrenia, major depressive disorder, bipolar disorder, or an anxiety disorder such as OCD or PTSD - Hospitalized for a psychological condition within the last 6 months - Unwilling to stop taking nutritional supplements, including probiotics, two weeks before the exercise tests. - Unwilling to stop pain medication and stimulant medication two days before the exercise tests. - Smoker, or stopped smoking less than 1 year ago - Pregnant or breastfeeding - Diabetic - Have an orthopedic limitation that prohibits cycle exercise - Excessive alcohol consumption Healthy Volunteers: Inclusion Criteria: - Healthy - Low-active - Adults 18 to 70 years of age Exclusion Criteria: - Recent history of panic attacks within the past 6 months - Diagnosis of schizophrenia, major depressive disorder, bipolar disorder, or an anxiety disorder such as OCD or PTSD - Hospitalized for a psychological condition within the last 6 months - Unwilling to stop taking nutritional supplements, including probiotics, two weeks before the exercise tests. - Unwilling to stop pain medication and stimulant medication two days before the exercise tests. - Smoker, or stopped smoking less than 1 year ago - Pregnant or breastfeeding - Diabetic - Have an orthopedic limitation that prohibits cycle exercise - Excessive alcohol consumption |
Country | Name | City | State |
---|---|---|---|
United States | Ithaca College | Ithaca | New York |
United States | Weill Cornell Medicine | New York | New York |
United States | ID Med | Torrance | California |
Lead Sponsor | Collaborator |
---|---|
Ithaca College | Cornell University, Weill Medical College of Cornell University, Workwell Foundation |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Volume of oxygen consumed at peak effort | Volume of oxygen consumed at peak effort during CPET 1 and during CPET 2. | During intervention on day 1 and during intervention on day 2; assessed through study completion, approximately 4 years from study start date. | |
Primary | Volume of oxygen consumed at ventilatory/anaerobic threshold (VAT) | VAT is a non-invasive surrogate measure for anaerobic threshold, which is indicated during incremental exercise by a non-linear increase in rate of carbon dioxide production relative to rate of oxygen consumption. | During intervention on day 1 and during intervention on day 2; assessed through study completion, approximately 4 years from study start date. | |
Primary | Rate of work performed at peak effort | Rate of work performed at peak effort during CPET 1 and during CPET 2. Rate of work is measured in Watts. | During intervention on day 1 and during intervention on day 2; assessed through study completion, approximately 4 years from study start date. | |
Primary | Rate of work performed at VAT | Rate of work performed at VAT during CPET 1 and during CPET 2. Rate of work is measured in Watts. | During intervention on day 1 and during intervention on day 2; assessed through study completion, approximately 4 years from study start date. | |
Primary | Heart rate at peak effort | Heart rate at peak effort during CPET 1 and during CPET 2. | During intervention on day 1 and during intervention on day 2; assessed through study completion, approximately 4 years from study start date. | |
Primary | Heart rate at VAT | Heart rate at VAT during CPET 1 and during CPET 2. | During intervention on day 1 and during intervention on day 2; assessed through study completion, approximately 4 years from study start date. | |
Primary | Systolic blood pressure at seated rest | Systolic blood pressure at seated rest 1-minute before the start of CPET 1 and 1-minute before the start of CPET 2. | During intervention on day 1 and during intervention on day 2; assessed through study completion, approximately 4 years from study start date. | |
Primary | Systolic blood pressure at peak effort | Systolic blood pressure at peak effort during CPET 1 and during CPET 2. | During intervention on day 1 and during intervention on day 2; assessed through study completion, approximately 4 years from study start date. | |
Primary | Respiratory Exchange Ratio (RER) at peak effort | RER at peak effort during CPET 1 and during CPET 2. RER is calculated as the rate of carbon dioxide production divided by the rate of oxygen consumption, and during exercise is an indicator of participant effort. | During intervention on day 1 and during intervention on day 2; assessed through study completion, approximately 4 years from study start date. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05454683 -
Melatonin and Zinc Administration on Cardinal Symptoms in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
|
N/A | |
Completed |
NCT01686074 -
Motor Control in Chronic Fatigue Syndrome and Fibromyalgia
|
N/A | |
Completed |
NCT02075489 -
Acupressure for Pain Management and Fatigue Relief in Gulf War Veterans
|
N/A | |
Completed |
NCT01651754 -
Humoral and Cellular Immune Responses After Influenza Vaccination in Patients With Postcancer Fatigue and in Patients With Chronic Fatigue Syndrome
|
N/A | |
Completed |
NCT00540254 -
Behavioral Insomnia Therapy With Chronic Fatigue Syndrome
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT00071162 -
Genetics of Fibromyalgia
|
N/A | |
Withdrawn |
NCT04870476 -
Feasibility and Acceptability of the Internet-delivered Treatment "One Step at the Time" for Bodily Distress Syndrome
|
N/A | |
Completed |
NCT05730660 -
Quercetin Phytosome® Chronic Fatigue Syndrome
|
N/A | |
Recruiting |
NCT04542161 -
Assessment of N-Acetylcysteine as Therapy for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
|
Phase 2 | |
Recruiting |
NCT03807973 -
Tracking Peripheral Immune Cell Infiltration of the Brain in Central Inflammatory Disorders Using [Zr-89]Oxinate-4-labeled Leukocytes.
|
Phase 1 | |
Recruiting |
NCT05719493 -
Effectiveness and Health Benefits of a Nutritional, Chronobiological and Physical Exercise Intervention in Fibromyalgia and Chronic Fatigue Syndrome (SYNCHRONIZE +)
|
N/A | |
Recruiting |
NCT05967052 -
Investigation of Treating Chronic Fatigue Syndrome After COVID With Pharmacotherapy (Pregabalin) or Complex Rehabilitation
|
Phase 2 | |
Terminated |
NCT01730495 -
Tumor Necrosis Factor-alpha Inhibition Using Etanercept in Chronic Fatigue Syndrome
|
Phase 2 | |
Completed |
NCT01650636 -
Patient-Partner Stress Management Effects on Chronic Fatigue Syndrome Symptoms and Neuroimmune Process
|
N/A | |
Completed |
NCT01156909 -
B-cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome
|
Phase 2 | |
Completed |
NCT01046370 -
A Pilot Study of Amygdala Retraining Program in Patients With Chronic Fatigue Syndrome, Chronic Fatigue and Fibromyalgia
|
N/A | |
Completed |
NCT00100412 -
Hyporeactivity and Gulf War Illness
|
N/A | |
Recruiting |
NCT06128967 -
A Multicenter, Adaptive, Randomized, doublE-blinded, Placebo-controlled Study in Participants With Long COVID-19: The REVIVE Trial
|
Phase 3 | |
Completed |
NCT02669212 -
Myalgic Encephalomyelitis Chronic Fatigue at the National Institutes of Health
|
N/A | |
Not yet recruiting |
NCT06011135 -
Exploring Worry in CFS/ME
|